| Citation: |
SHEN Yingxiao, SHI Huihai, LUO Jiale, ZHANG Xing, XU Ting, GUO Heming, ZHOU Chunxiao. Application and progress of liver fibrosis risk prediction model for nonalcoholic fatty liver disease[J]. Journal of Clinical Medicine in Practice, 2023, 27(9): 131-136, 142. DOI: 10.7619/jcmp.20222652
|
The incidence of non-alcoholic fatty liver disease is increasing year by year. Early evaluation and early intervention of fatty liver fibrosis are very important for improving the prognosis of patients with non-alcoholic fatty liver disease. Non-invasive prediction models have been paid more and more attention in clinical practice. Based on different clinical indexes and algorithms, the article systematically reviewed the advantages and limitations ofvarious models for predicting liver fibrosis, and analyzed the characteristics of each model and its value.
| [1] |
GEOFFREY C F, CLAIRE Z L. Nonalcoholic fatty liver disease: from steatosis to cirrhosis[J]. Hepatology, 2006, 43(2 Suppl 1): S99-S112.
|
| [2] |
DE ALWIS N M, DAY C P. Non-alcoholic fatty liver disease: the mist gradually clears[J]. J Hepatol, 2008, 48(Suppl 1): S104-S112.
|
| [3] |
BELLENTANI S, SCAGLIONI F, MARINO M, et al. Epidemiology of non-alcoholic fatty liver disease[J]. Dig Dis, 2010, 28(1): 155-161. doi: 10.1159/000282080
|
| [4] |
FAN J G, FARRELL G C. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1): 204-210. doi: 10.1016/j.jhep.2008.10.010
|
| [5] |
GHOLAM P M, FLANCBAUM L, MACHAN J T, et al. Nonalcoholic fatty liver disease in severely obese subjects[J]. Am J Gastroenterol, 2007, 102(2): 399-408. doi: 10.1111/j.1572-0241.2006.01041.x
|
| [6] |
RATZIU V, BELLENTANI S, CORTEZ-PINTO H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference[J]. J Hepatol, 2010, 53(2): 372-384. doi: 10.1016/j.jhep.2010.04.008
|
| [7] |
FAN J G, SAIBARA T, CHITTURI S, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific[J]. J Gastroenterol Hepatol, 2007, 22(6): 794-800. doi: 10.1111/j.1440-1746.2007.04952.x
|
| [8] |
LEE D H. Noninvasive evaluation of nonalcoholic fatty liver disease[J]. Endocrinol Metab Seoul Korea, 2020, 35(2): 243-259. doi: 10.3803/EnM.2020.35.2.243
|
| [9] |
RINELLA M E, SANYAL A J. Management of NAFLD: a stage-based approach[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(4): 196-205. doi: 10.1038/nrgastro.2016.3
|
| [10] |
UNALP-ARIDA A, RUHL C E. Liver fibrosis scores predict liver disease mortality in the United States population[J]. Hepatology, 2017, 66(1): 84-95. doi: 10.1002/hep.29113
|
| [11] |
TOBARI M, HASHIMOTO E, TANIAI M, et al. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis[J]. J Gastroenterol Hepatol, 2020, 35(5): 862-869. doi: 10.1111/jgh.14867
|
| [12] |
FORNS X, AMPURDANÉS S, LLOVET J M, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model[J]. Hepatology, 2002, 36(4 pt 1): 986-992.
|
| [13] |
LEE J, VALI Y, BOURSIER J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review[J]. Liver Int, 2021, 41(2): 261-270. doi: 10.1111/liv.14669
|
| [14] |
MCPHERSON S, HARDY T, DUFOUR J F, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis[J]. Am J Gastroenterol, 2017, 112(5): 740-751. doi: 10.1038/ajg.2016.453
|
| [15] |
PARK H, YOON E L, KIM M, et al. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era[J]. Hepatol Res, 2022, 52(3): 247-254. doi: 10.1111/hepr.13737
|
| [16] |
NABI O, LACOMBE K, BOURSIER J, et al. Risk factors of nonalcoholic fatty liver disease and advanced fbrosis in general population: the French nationwide NASH-CO study[J]. Gastroenterology, 2020, 159: 791-793. doi: 10.1053/j.gastro.2020.04.048
|
| [17] |
YANG H R, KIM H R, KIM M J, et al. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2012, 18(13): 1525-1530. doi: 10.3748/wjg.v18.i13.1525
|
| [18] |
WAI C T, GREENSON J K, FONTANA R J, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38(2): 518-526. doi: 10.1053/jhep.2003.50346
|
| [19] |
LIN Z H, XIN Y N, DONG Q J, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis[J]. Hepatology, 2011, 53(3): 726-736. doi: 10.1002/hep.24105
|
| [20] |
KRUGER F C, DANIELS C R, KIDD M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH[J]. S Afr Med J, 2011, 101(7): 477-480.
|
| [21] |
RIGAMONTI A E, BONDESAN A, RONDINELLI E, et al. The role of aspartate transaminase to platelet ratio index (APRI) for the prediction of non-alcoholic fatty liver disease (NAFLD) in severely obese children and adolescents[J]. Metabolites, 2022, 12(2): 155. doi: 10.3390/metabo12020155
|
| [22] |
RATZIU V, GIRAL P, CHARLOTTE F, et al. Liver fibrosis in overweight patients[J]. Gastroenterology, 2000, 118(6): 1117-1123. doi: 10.1016/S0016-5085(00)70364-7
|
| [23] |
LEE T H, HAN S H, YANG J D, et al. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD score[J]. Gut Liver, 2013, 7(3): 323-328. doi: 10.5009/gnl.2013.7.3.323
|
| [24] |
DEMIR M, LANG S, SCHLATTJAN M, et al. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD[J]. PLoS One, 2013, 8(3): e58360. doi: 10.1371/journal.pone.0058360
|
| [25] |
SUMIDA Y, YONEDA M, HYOGO H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease[J]. J Gastroenterol, 2011, 46(2): 257-268. doi: 10.1007/s00535-010-0305-6
|
| [26] |
NAKAMURA A, YONEDA M, SUMIDA Y, et al. Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease[J]. J Diabetes Investig, 2013, 4(6): 651-658. doi: 10.1111/jdi.12101
|
| [27] |
胡梦琪, 徐有青, 张涛, 等. 非酒精性脂肪性肝炎的无创诊断方法[J]. 临床肝胆病杂志, 2017, 33(12): 2288-2291. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD201712007.htm
|
| [28] |
FERNANDES F F, FERRAZ M L, ANDRADE L E, et al. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients[J]. J Clin Gastroenterol, 2015, 49(3): 235-241. doi: 10.1097/MCG.0000000000000128
|
| [29] |
NOBILI V, PARKES J, BOTTAZZO G, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease[J]. Gastroenterology, 2009, 136(1): 160-167. doi: 10.1053/j.gastro.2008.09.013
|
| [30] |
BOURSIER J, VERGNIOL J, GUILLET A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 65(3): 570-578. doi: 10.1016/j.jhep.2016.04.023
|
| [31] |
ADAMS L A, BULSARA M, ROSSI E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection[J]. Clin Chem, 2005, 51(10): 1867-1873. doi: 10.1373/clinchem.2005.048389
|
| [32] |
HUANG Y, ADAMS L A, JOSEPH J, et al. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis[J]. Liver Int, 2017, 37(1): 121-131. doi: 10.1111/liv.13116
|
| [33] |
POYNARD T, RATZIU V, CHARLOTTE F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2006, 6: 34. doi: 10.1186/1471-230X-6-34
|
| [34] |
POYNARD T, LASSAILLY G, DIAZ E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data[J]. PLoS One, 2012, 7(3): e30325. doi: 10.1371/journal.pone.0030325
|
| [35] |
HARRISON S A, RATZIU V, BOURSIER J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(11): 970-985. doi: 10.1016/S2468-1253(20)30252-1
|
| [36] |
ZHOU Y, ORESIC M, LEIVONEN M, et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites[J]. Clin Gastroenterol Hepatol, 2016, 14(10): 1463-1472. doi: 10.1016/j.cgh.2016.05.046
|
| [37] |
IMBERT-BISMUT F, RATZIU V, PIERONI L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study[J]. Lancet, 2001, 357(9262): 1069-1075. doi: 10.1016/S0140-6736(00)04258-6
|
| [38] |
MUNTEANU M, TINIAKOS D, ANSTEE Q, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference[J]. Aliment Pharmacol Ther, 2016, 44(8): 877-889. doi: 10.1111/apt.13770
|
| [39] |
GUILLAUME M, MOAL V, DELABAUDIERE C, et al. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres[J]. Aliment Pharmacol Ther, 2019, 50(11/12): 1214-1222.
|
| [40] |
VAN DIJK A M, VALI Y, MAK A L, et al. Systematic review with meta-analyses: diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease[J]. J Clin Med, 2021, 10(13): 2910. doi: 10.3390/jcm10132910
|
| [41] |
The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases[J]. Clin Liver Dis: Hoboken, 2018, 11(4): 81.
|
| [42] |
ADAMS L A, GEORGE J, BUGIANESI E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2011, 26(10): 1536-1543. doi: 10.1111/j.1440-1746.2011.06774.x
|
| [43] |
SRIVASTAVA A, JONG S, GOLA A, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2019, 19(1): 122. doi: 10.1186/s12876-019-1039-4
|
| [44] |
SRIVASTAVA A, JONG S, GOLA A, et al. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2019, 19(1): 122. doi: 10.1186/s12876-019-1039-4
|
| 1. |
王文琪，史菁菁，王嘉慧，南丽虹，路红. 仿生纳米粒在乳腺癌治疗及成像研究进展. 中华实验外科杂志. 2024(04): 865-870 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: